Conditions: Gastroesophageal Reflux Disease (GERD)
Keywords: Gastroesophageal Reflux Disease GERD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 240
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the efficacy of rabeprazole extended release (ER) 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).

Detailed description:
This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all eligibility criteria will be randomly assigned to 1 of 2 treatment groups, RAB ER 50 mg (once daily) or Ranitidine 150 mg (twice daily).

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Rabeprazole ER intervention 2: Ranitidine
Intervention descriptions: intervention 1: 50 mg capsule, taken orally, once daily for 26 weeks. intervention 2: 150 mg capsule, taken orally, twice daily for 26 weeks.

Protocol document: